Thus, we evaluated RNA-based signatures for TP53 and HRD in association with tumor immune profiles in 1,942 patients from the Carolina Breast Cancer Study (CBCS; n = 1,026 Black, 916 non-Black), with validation in two publicly available datasets [the Cancer Genome Atlas (TCGA; n = 1,046) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; n = 1,904)]. The gene discussed is TP53; the disease is breast carcinoma.